Tag: meeting

Press release – Neuilly-sur-Seine, Tuesday, July 8, 2025 - 5.45 pm

SEOUL, South Korea, July 08, 2025 (GLOBE NEWSWIRE) -- DoubleDown Interactive Co., Ltd. (NASDAQ: DDI) (“DoubleDown” or the “Company”), a leading gaming company delivering exceptional player experiences across multiple genres, announced today that the Company entered into a Share Purchase and Transfer Agreement with Azerion Tech Holding B.V. to acquire WHOW Games GmbH, a social casino developer headquartered in Hamburg, Germany. The initial consideration for 100% ownership interest in WHOW Games is €55 million (approximately $64.7 million⁽¹⁾). An additional earn-out payment of up to €10 million, payable to Azerion at €5 million annually, is contingent upon WHOW Games meeting certain performance targets during each of the first and second year following the closing date. The acquisition will be financed through DoubleDown’s cash reserves and is expected to close during the third quarter of 2025.

8 July 2025 - Reference is made to the stock exchange announcement made by Prosafe SE (the "Company") on 16 May 2025 regarding the extraordinary general meeting's resolution to decrease the share capital of the Company by EUR 22,157,127.24, from EUR 22,335,813.75 to EUR 178,686.51, through a decrease of the nominal value of each share in the Company by EUR 1.24, from EUR 1.25 to EUR 0.01.

- IDE approval obtained; U.S. pilot study clinical site launched at Johns Hopkins
- Series B round in planning to support pivotal U.S. trial
- New CEO appointment signals next phase of growth and expansion

According to Precedence Research, the global web3 gaming market size is calculated at USD 37.55 billion in 2025 and is expected to be worth around USD 182.98 billion by 2034, registering a robust CAGR of 19.24% from 2025 to 2034. North America accounted for USD 11.34 billion in 2024 and is poised to maintain its dominance with a double-digit CAGR of 19.40%.

BRÜSSEL, July 08, 2025 (GLOBE NEWSWIRE) -- Die Notwendigkeit, einen Fonds aus dem EU-Haushalt einzurichten, um die Produktion kritischer Arzneimittel in Europa zu unterstützen, ist eine Schlussfolgerung aus einer Analyse der Auswirkungen des Krieges auf die Verfügbarkeit von Arzneimitteln in der Ukraine. Medicines for Poland: Die Europäische Kommission sollte die bestehende Pharmaindustrie in Europa konkret unterstützen, um die Verlagerung der Produktion kritischer Arzneimittel und ihrer Inhaltsstoffe zurück in die EU zu ermöglichen, wobei der Schwerpunkt auf Mittel- und Osteuropa als Region mit hohem industriellem Potenzial liegen sollte.